The trial aims to evaluate the safety and efficacy of CRLX101 in patients with advanced NSCLC whose disease has progressed following one or two prior regimens of therapy.
The company expects to recruit around 150 patients in the trial across 26 sites in Russia and Ukraine.
Cerulean chief medical officer Edward Garmey said based on exciting preclinical and clinical data, CRLX101 has the potential to be effective in both squamous and non-squamous histology patient populations, as well as in patients with a variety of tumor mutational markers including KRAS and EGFR.